Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


19 Items
Title  Creator  Group name  Publishing year 
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program Le Du et al. EquipeCTCS 2023-10-03
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study François-Martin et al. EquipeELC 2023-02-13
Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study Falandry et al. EquipePC 2022-03
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial Bidard et al. EquipePC 2022-11
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study Dalenc et al. EquipeELC 2022-03
Genomics to select treatment for patients with metastatic breast cancer Andre et al. EquipeCTCS 2022-10
Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort Moinard-Butot et al. EquipeCTCS 2022-06
Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study Vasseur et al. EquipeELC 2022-10
Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France de Calbiac et al. EquipePC 2022-09-01
Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program Cabel et al. EquipeCTCS 2021-04
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer Bortolini Silveira et al. EquipeCTCS 2021-09-09
Impact of body mass index on overall survival in patients with metastatic breast cancer Saleh et al. EquipePC 2021-02
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial Falandry et al. EquipePC 2021-06-01
Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study Heudel et al. EquipePC Jul 2020
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort Frank et al. EquipePC Aug 2020
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program Jacot et al. EquipeCTCS May 14, 2019
Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET) Vasseur et al. EquipeCTCS Nov 26, 2019
Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens Cabel et al. EquipeCTCS Jan 2019
Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model Trédan et al. EquipeELC Jun 2015
19 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés